ApoE and Clusterin Cooperatively Suppress Aβ Levels and Deposition: Evidence that ApoE Regulates Extracellular Aβ Metabolism In Vivo

Neuron

Volumn 41, Issue 2, 2004, Pages 193-202

  DeMattos, Ronald B ^a   Cirrito, John R ^e   Parsadanian, Maia ^e   May, Patrick C ^a   O'Dell, Mark A ^e   Taylor, Jennie W ^e   Harmony, Judith A K ^b   Aronow, Bruce J ^c   Bales, Kelly R ^a   Paul, Steven M ^a,d   Holtzman, David M ^e  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^d INDIANA UNIVERSITY   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; CLUSTERIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN METABOLISM; HALF LIFE TIME; INTERSTITIAL FLUID; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN METABOLISM; TRANSGENIC MOUSE;

EID: 9144224765     PISSN: 08966273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0896-6273(03)00850-X     Document Type: Article

References (59)

1. Bales K.R., Verina T., Dodel R.C., Du Y., Altstiel L., Bender M., Hyslop P., Johnstone E.M., Little S.P., Cummins D.J.et al. Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nat. Genet. 17:1997;263-264.
2. Bales K.R., Verina T., Cummins D.J., Du Y., Dodel J.C., Saura J., Fishman C.E., DeLong C.A., Piccardo P., Petegnief V.et al. Apolipoprotein E is essential for amyloid deposition in the APPV717F transgenic mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 96:1999;15233-15238.
3. Beffert U., Aumont N., Dea D., Lussier-Cacan S., Davignon J., Poirier J. Apolipoprotein E isoform-specific reduction of extracellular amyloid in neuronal cultures. Mol. Brain Res. 68:1999;181-185.
4. Biere A.L., Ostaszewski B., Zhao H., Gillespie S., Younkin S.G., Selkoe D.J. Co-expression of beta-amyloid precursor protein (betaAPP) and apolipoprotein E in cell culture. analysis of betaAPP processing Neurobiol. Dis. 2:1995;177-187.
5. Boggs L.N., Fuson K.S., Baez M., Churgay L., McClure D., Becker G., May P.C. Clusterin (apoJ) protects against in vitro amyloid-β(1-40) neurotoxicity. J. Neurochem. 67:1996;1324-1327.
6. Borchelt D.R., Ratovitski T., Van Lare J., Lee M.K., Gonzales V.B., Jenkins N.A., Copeland N.G., Price D.L., Sisodia S.S. Accelerated amyloid deposition in the brains of transgenic mice co-expressing mutant presenilin 1 and amyloid precursor proteins. Neuron. 19:1997;939-945.
7. Boyles J.K., Pitas R.E., Wilson E., Mahley R.W., Taylor J.M. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J. Clin. Invest. 76:1985;1501-1513.
8. Calero M., Rostagno A., Matsubara E., Zlokovic B., Frangione B., Ghiso J. Apolipoprotein J (clusterin) and Alzheimer's disease. Microsc. Res. Tech. 50:2000;305-315.
9. Castano E.M., Prelli F., Wisniewski T., Golabek A., Kumar R.A., Soto C., Frangione B. Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E. Biochem. J. 306:1995;599-604.
10. Cirrito J.R., May P.C., O'Dell M.A., Taylor J.W., Parsadanian M., Cramer J.W., Audia J.E., Nissen J.S., Bales K.R., Paul S.M.et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-β metabolism and half-life. J. Neurosci. 23:2003;8844-8853.
11. Corder E.H., Saunders A.M., Risch N.J., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Rimmler J.B., Locke P.A., Conneally P.M., Schmader K.E.et al. Protective effect of apolipoprotein E type 2 allele decreases risk of late onset Alzhimer disease. Nat. Genet. 7:1994;180-184.
12. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.-C., Paul S.M., Holtzman D.M. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 98:2001;8850-8855.
13. DeMattos R.B., Bales K., Cummins D.J., Paul S.M., Holtzman D.M. Brain to plasma amyloid-β efflux. A measure of brain amyloid burden in a mouse model of Alzheimer's disease Science. 295:2002;2264-2267. a.
14. DeMattos R.B., Bales K.R., Parsadanian M., Kierson M.E., O'Dell M.A., Foss E.M., Paul S.M., Holtzman D.M. Plaque-associated disruption of CSF and plasma Aβ equilibrium in a mouse model of Alzheimer's Disease. J. Neurochem. 81:2002;229-236. b.
15. DeMattos R.B., O'dell M.A., Parsadanian M., Taylor J.W., Harmony J.A.K., Bales K.R., Paul S.M., Aronow B.J., Holtzman D.M. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 10:2002;10843-10848. c.
16. Duff K., Eckman C., Zehr C., Yu X., Prada C.M., Perez-tur J., Hutton M., Buee L., Harigaya Y., Yager D.et al. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature. 383:1996;710-713.
17. Fagan A.M., Younkin L.H., Morris J.C., Cole T.G., Younkin S.G., Holtzman D.M. Differences in Aβ40/42 ratio associated with CSF lipoproteins as a function of apoE genotype. Ann. Neurol. 48:2000;201-210.
18. Fagan A.M., Watson M., Parsadanian M., Bales K.R., Paul S.M., Holtzman D.M. Human and murine apoE markedly influence Aβ metabolism both prior and subsequent to plaque formation in a mouse model of Alzheimer's disease. Neurobiol. Dis. 9:2002;305-318.
19. Fryer J.D., Taylor J.W., DeMattos R.B., Bales K.R., Paul S.M., Parsadanian M., Holtzman D.M. Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in APP transgenic mice. J. Neurosci. 23:2003;7889-7896.
20. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F.et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature. 373:1995;523-527.
21. Ghiso J., Matsubara E., Koudinov A., Choi-Miura N.H., Tomita M., Wisniewski T., Frangione B. The cerebrospinal-fluid form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem. J. 293:1993;27-30.
22. Greenberg S.M., Rebeck G.W., Vonsattel J.P.G., Gomez-Isla T., Hyman B.T. Apolipoprotein E ε4 and cerebral hemorrhage associated with amyloid angiopathy. Ann. Neurol. 38:1995;254-259.
23. Hammad S.M., Ranganathan S., Loukinova E., Twal W.O., Argraves W.S. Interaction of apolipoprotein J-amyloid beta-peptide complex with low density lipoprotein receptor-related protein-2/megalin. A mechanism to prevent pathological accumulation of amyloid beta peptide. J. Biol. Chem. 272:1997;18644-18649.
24. Han B.H., DeMattos R.B., Dugan L.L., Kim-Han J.S., Brendza R., Fryer J.D., Kierson M., Cirrito J., Quick K., Harmony J.A.K.et al. Clusterin contributes to caspase-3 independent brain injury following neonatal hypoxia-ischemia. Nat. Med. 7:2001;338-343.
25. Holtzman D.M. Role of apoE/Aβ interactions in the pathogenesis of Alzheimer's disease and cerebral amyloid angiopathy. J. Mol. Neurosci. 17:2001;147-155.
26. Holtzman D.M., Bales K.R., Wu S., Bhat P., Parsadanian M., Fagan A.M., Chang L.K., Sun Y., Paul S.M. In vivo expression of apolipoprotein E reduces amyloid-β deposition in a mouse model of Alzheimer's disease. J. Clin. Invest. 103:1999;R15-R21.
27. Holtzman D.M., Bales K.R., Tenkova T., Fagan A.M., Parsadanian M., Sartorius L.J., Mackey B., Olney J., McKeel D., Wozniak D., Paul S.M. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 97:2000;2892-2897. a.
28. Holtzman D.M., Fagan A.M., Mackey B., Tenkova T., Sartorius L., Paul S.M., Bales K., Ashe K.H., Irizzary M.C., Hyman B.T. ApoE facilitates neuritic and cerebrovascular plaque formation in the APPsw mouse model of Alzheimer's disease. Ann. Neurol. 47:2000;739-747. b.
29. Joachim C.L., Duffy L.K., Morris J.H., Selkoe D.J. Protein chemical and immunocytochemical studies of meningovascular β-amyloid protein in Alzheimer's disease and normal aging. Brain Res. 474:1988;100-111.
30. Johnson-Wood K., Lee M., Motter R., Hu K., Gordon G., Barbour R., Khan K., Gordon M., Tan H., Games D.et al. Amyloid precursor protein processing and Aß42 deposition in a transgenic mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 94:1997;1550-1555.
31. LaDu M.J., Falduto M.T., Manelli A.M., Reardon C.A., Getz G.S., Frail D.E. Isoform-specific binding of apolipoprotein E to β-amyloid. J. Biol. Chem. 269:1994;23404-23406.
32. LaDu M.J., Pederson T.M., Frail D.E., Reardon C.A., Getz G.S., Falduto M.T. Purification of apolipoprotein E attenuates isoform-specific binding to β-amyloid. J. Biol. Chem. 270:1995;9030-9042.
33. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatsos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L.et al. Diffusible, nonfibrillar ligands derived from Aß1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA. 95:1998;6448-6453.
34. Ma J., Yee A., Brewer H.B., Das S., Potter H. Amyloid-associated proteins alpha-1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature. 372:1994;92-94.
35. Matsubara E., Soto C., Governale S., Frangione B., Ghiso J. Apolipoprotein J and Alzheimer's amyloid beta solubility. Biochem. J. 316:1996;671-679.
36. Matsubara E., Ghiso J., Frangione B., Amari M., Tomidokoro Y., Ikeda Y., Harigaya Y., Okamoto K., Shoji M. Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome. Ann. Neurol. 45:1999;537-541.
37. May P.C., Finch C.E. Sulfated glycoprotein 2. new relationships of this multifunctional protein to neurodegeneration Trends Neurosci. 15:1992;391-396.
38. McLaughlin L., Zhu G., Mistry M., Ley-Ebert C., Stuart W.D., Florio C.J., Groen P.A., Witt S.A., Kimball T.R., Witte D.P.et al. Apolipoprotein J/clusterin limits the severity of murine autoimmune myocarditis. J. Clin. Invest. 106:2000;1105-1113.
39. Menacherry S., Hubert W., Justice J.B.J. In vivo calibration of microdialysis probes for exogenous compounds. Anal. Chem. 64:1992;577-583.
40. Nicoll J.A.R., Burnett C., Love S., Graham D.I., Dewar D., Ironside J.W., Stewart J., Vinters H.V. High frequency of apolipoprotein E ε2 allele in hemorrhage due to cerebral amyloid angiopathy. Ann. Neurol. 41:1997;716-721.
41. Oda T., Wals P., Osterburg H.H., Johnson S.A., Pasinetti G.M., Morgan T.M., Rozovsky I., Stine W.B., Snyder S.W., Holzman T.F.et al. Clusterin (apoJ) alters the aggregation of amyloid β-peptide (Aβ1-42) and forms slowly sedimenting Aβ complexes that cause oxidative stress. Exp. Neurol. 136:1995;22-31.
42. Russo C., Angelini G., Dapino D., Piccini A., Piombo G., Schettini G., Chen S., Teller J.K., Zaccheo D., Gambetti P., Tabaton M. Opposite roles of apolipoprotein E in normal brains and in Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 95:1998;15598-15602.
43. Schmechel D.E., Saunders A.M., Strittmattter W.J., Crain B.J., Hulette C.M., Joo S.H., Pericak-Vance M.A., Goldgaber D., Roses A.D. Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein genotype in late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA. 90:1993;9649-9653.
44. Selkoe D.J. Alzheimer's disease. genes, proteins, and therapy Physiol. Rev. 81:2001;741-766.
45. Shibata M., Yamada S., Kumar S.R., Calero M., Bading J., Frangione B., Holtzman D.M., Miller C.A., Strickland D.K., Ghiso J., Zlokovic B.V. Clearance of Alzheimer's amyloid-β1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 106:2000;1489-1499.
46. Sisodia S.S. Alzheimer's disease. perspectives for the new millennium J. Clin. Invest. 104:1999;1169-1170.
47. Sisodia S.S., Koo E.H., Hoffman P.N., Perry G., Price D.L. Identification and transport of full-length amyloid precursor proteins in rat peripheral nervous system. J. Neurosci. 13:1993;3136-3142.
48. Strittmatter W.J., Bova Hill C. Molecular biology of apolipoprotein E. Curr. Opin. Lipidol. 13:2002;119-123.
49. Strittmatter W.J., Roses A.D. Apolipoprotein E and Alzheimer's disease. Annu. Rev. Neurosci. 19:1996;53-77.
50. Strittmatter W.J., Saunders A.M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G.S., Roses A.D. Apolipoprotein E. high avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease Proc. Natl. Acad. Sci. USA. 90:1993;1977-1981. a.
51. Strittmatter W.J., Weisgraber K.H., Huang D.Y., Dong L.-Y., Salvesen G.S., Pericak-Vance M., Schmechel D., Saunders A.M., Goldgaber D., Roses A.D. Binding of human apolipoprotein E to synthetic amyloid β peptide. isoform specific-effects and implications for late-onset Alzheimer disease Proc. Natl. Acad. Sci. USA. 90:1993;8098-8102. b.
52. Sun Y., Wu S., Bu G., Onifade M.K., Patel S.N., LaDu M.J., Fagan A.M., Holtzman D.M. GFAP-apoE transgenic mice. Astrocyte specific expression and differing biological effects of astrocyte-secreted apoE3 and apoE4 lipoproteins J. Neurosci. 18:1998;3261-3272.
53. Tokuda T., Calero M., Matsubara E., Vidal R., Kumar A., Permanne B., Zlokovic B., Smith J.D., Ladu M.J., Rostagno A.et al. Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides. Biochem. J. 348:2000;359-365.
54. Urmoneit B., Prikulis I., Wihl G., D'Urso D., Frank R., Heeren J., Beisiegel U., Prior R. Cerebrovascular smooth muscle cells internalize Alzheimer amyloid beta protein via a lipoprotein pathway. Implications for cerebral amyloid angiopathy Lab. Invest. 77:1997;157-166.
55. Williams D.L., Wong J.S., Wissig S.L., Hamilton R.L. Cell surface "blanket" of apolipoprotein E on rat adrenocortical cells. J. Lipid Res. 36:1995;745-758.
56. Wisniewski T., Frangione B. Apolipoprotein E. a pathological chaperone protein in patients with cerebral and systemic amyloid Neurosci. Lett. 135:1992;235-238.
57. Wisniewski T., Ghiso J., Frangione B. Biology of Aß amyloid in Alzheimer's disease. Neurobiol. Dis. 4:1997;313-328.
58. Yang D.S., Small D.H., Seydel U., Smith J.D., Hallmayer J., Gandy S.E., Martins R.N. Apolipoprotein E promotes the binding and uptake of beta-amyloid into Chinese hamster ovary cells in an isoform-specific manner. Neuroscience. 90:1999;1217-1226.
59. Zlokovic B.V., Martel C.L., Matsubara E., McComb J.G., Zheng G., McCluskey R.T., Frangione B., Ghiso J. Glycoprotein 330/megalin. probably role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer's disease amyloid β at the blood-brain and blood-cerebrospinal fluid barriers Proc. Natl. Acad. Sci. USA. 93:1996;4229-4234.